NEW YORK,
Jan. 24,
2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:
HOTH) (the "Company" or "Hoth Therapeutics"), a biopharmaceutical
company, today announced that it has received notification from the
Listing Qualifications Department of The Nasdaq Stock Market LLC
("Nasdaq") that the Company has regained compliance with Nasdaq's
minimum bid price requirement under Listing Rule 5550(a)(2).
The Company received written notification from
Nasdaq on January 23, 2025, stating
that because the Company's common stock had a closing bid price at
or above $1.00 per share for 10
consecutive business days, from January 7,
2025 to January 22, 2025, the
Company has regained compliance with Listing Rule 5550(a)(2), and
this matter is now closed.
"We are pleased to report that Hoth Therapeutics
has achieved compliance with Nasdaq's minimum bid price
requirement," said Robb Knie, CEO of
Hoth Therapeutics. "This milestone reinforces our commitment to
creating long-term shareholder value and demonstrates our
dedication to meeting the highest standards of corporate governance
and performance."
Hoth Therapeutics remains dedicated to advancing
its pipeline and its delivering impactful healthcare solutions to
improve patient outcomes.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage
biopharmaceutical company dedicated to developing innovative,
impactful, and ground-breaking treatments with a goal to improve
patient quality of life. We are a catalyst in early-stage
pharmaceutical research and development, elevating drugs from the
bench to pre-clinical and clinical testing. Utilizing a
patient-centric approach, we collaborate and partner with a team of
scientists, clinicians, and key opinion leaders to seek out and
investigate therapeutics that hold immense potential to create
breakthroughs and diversify treatment options. To learn more,
please visit https://ir.hoththerapeutics.com/.
Forward-Looking Statement
This press release includes forward-looking
statements based upon Hoth's current expectations, which may
constitute forward-looking statements for the purposes of the safe
harbor provisions under the Private Securities Litigation Reform
Act of 1995 and other federal securities laws, and are subject to
substantial risks, uncertainties, and assumptions. These statements
concern Hoth's business strategies; the timing of regulatory
submissions; the ability to obtain and maintain regulatory approval
of existing product candidates and any other product candidates we
may develop, and the labeling under any approval we may obtain; the
timing and costs of clinical trials, and the timing and costs of
other expenses; market acceptance of our products; the ultimate
impact of the current coronavirus pandemic, or any other health
epidemic, on our business, our clinical trials, our research
programs, healthcare systems, or the global economy as a whole; our
intellectual property; our reliance on third-party organizations;
our competitive position; our industry environment; our anticipated
financial and operating results, including anticipated sources of
revenues; our assumptions regarding the size of the available
market, benefits of our products, product pricing, and timing of
product launches; management's expectation with respect to future
acquisitions; statements regarding our goals, intentions, plans,
and expectations, including the introduction of new products and
markets; and our cash needs and financing plans. There are a number
of factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. You should not
place reliance on these forward-looking statements, which include
words such as "could," "believe," "anticipate," "intend,"
"estimate," "expect," "may," "continue," "predict," "potential,"
"project" or similar terms, variations of such terms, or the
negative of those terms. Although the Company believes that the
expectations reflected in the forward-looking statements are
reasonable, the Company cannot guarantee such outcomes. Hoth may
not realize its expectations, and its beliefs may not prove
correct. Actual results may differ materially from those indicated
by these forward-looking statements as a result of various
important factors, including, without limitation, market conditions
and the factors described in the section titled "Risk Factors" in
Hoth's most recent Annual Report on Form 10-K and Hoth's other
filings made with the U. S. Securities and Exchange Commission. All
such statements speak only as of the date made. Consequently,
forward-looking statements should be regarded solely as Hoth's
current plans, estimates, and beliefs. Investors should not place
undue reliance on forward-looking statements. Hoth cannot guarantee
future results, events, levels of activity, performance, or
achievements. Hoth does not undertake and specifically declines any
obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events, or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-regains-compliance-with-nasdaq-listing-requirements-302359435.html
SOURCE Hoth Therapeutics, Inc.